PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT APEXIGEN, INC.Pyxis Oncology, Inc. • August 23rd, 2023 • Pharmaceutical preparations
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is six months following the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _______, 20281 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Apexigen, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
BROOKLINE CAPITAL ACQUISITION CORP. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY AMENDED AND RESTATED WARRANT AGREEMENTWarrant Agreement • August 23rd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations • New York
WARRANT ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENTWarrant Assignment, Assumption and Amendment Agreement • August 23rd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations • New York
This WARRANT ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (this “Agreement”) is made as of August 23, 2023 by and among Apexigen, Inc. (as successor to Brookline Capital Acquisition Corp. (“BCAC”)), a Delaware corporation (“Apexigen”), Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company (the “Warrant Agent” or “Broadridge”) as successor to Continental Stock Transfer & Trust Company (“Continental”).
WARRANT ASSUMPTION AGREEMENTWarrant Assumption Agreement • August 23rd, 2023 • Pyxis Oncology, Inc. • Pharmaceutical preparations • New York
This WARRANT ASSUMPTION AGREEMENT (this “Agreement”) is made as of August 23, 2023 by and among Apexigen, Inc., a Delaware corporation (“Apexigen”), and Pyxis Oncology, Inc., a Delaware corporation (“Pyxis Oncology”).
